Metastatic Bone Disease Global Market Report 2024

The metastatic bone disease market size has grown strongly in recent years. It will grow from $15.6 billion in 2023 to $17.14 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to an increasing aging population, heightened cancer awareness programs, a growing demand for effective pain management therapies, significant investment in drug discovery and development, and the adoption of unhealthy lifestyles.

The metastatic bone disease market size is expected to see strong growth in the next few years. It will grow to $25.04 billion in 2028 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to an increasing geriatric population, a focus on developing novel radiopharmaceutical drugs, favorable reimbursement policies, the creation of cutting-edge treatments, growing demand for effective pain management therapies, and rising awareness about metastatic bone disease. Major trends during this period include technological advancements in diagnostics, improved diagnostic techniques, innovations in therapeutic approaches, the integration of artificial intelligence and machine learning algorithms, and advancements in the management of bone health.

The increasing prevalence of bone cancer is expected to propel the growth of the metastatic bone disease market. Bone cancer, a malignant tumor originating in the cells of the bone, is driven by genetic factors, radiation exposure, and environmental factors such as exposure to certain chemicals. Bone cancer can lead to metastatic bone disease as cancer cells from the primary tumor spread through the bloodstream or lymphatic system, forming new tumors in other bones. For instance, in 2023, the American Cancer Society, a US-based non-profit organization, reported 3,970 new cases of bone and joint cancer, an increase from the 3,910 cases reported in 2022. Therefore, the increasing prevalence of bone cancer is driving the growth of the metastatic bone disease market.

Major companies in the metastatic bone disease market are developing targeted therapies to improve treatment outcomes. These targeted therapies help in metastatic bone disease by precisely targeting cancer cells, minimizing damage to healthy cells, and offering a personalized treatment approach based on the individual patient's molecular characteristics. For example, in March 2022, Novartis AG, a Switzerland-based pharmaceutical company, introduced Zometa (zoledronic acid), a bisphosphonate medication approved for the prevention of skeletal-related events in patients with bone metastases from solid tumors and multiple myeloma. These advancements aim to improve treatment outcomes and quality of life for patients with metastatic bone disease.

In May 2024, Telix Pharmaceuticals Limited, an Australia-based biopharmaceutical company, acquired QSAM Biosciences for an undisclosed amount. This acquisition aims to bolster Telix's therapeutic pipeline, strengthening its position in radiopharmaceutical innovation and widening its focus on oncology and rare diseases. Through this deal, Telix intends to accelerate the development and delivery of treatments for bone metastases, aiming to provide significant benefits to affected patients. QSAM Biosciences Inc. is a US-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer.

Major companies operating in the metastatic bone disease market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Eli Lilly and Company, Amgen Inc., Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Jazz Pharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Mylan N.V., Novocure GmbH, Galapagos NV, Telix Pharmaceuticals Limited.

North America was the largest region in the metastatic bone disease market in 2023. The regions covered in the metastatic bone disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the metastatic bone disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Metastatic bone disease refers to the condition where cancer cells spread from their original (primary) site to the bones, causing bone weakening and symptoms such as pain, fractures, spinal cord compression, and hypercalcemia. This indicates that the cancer has progressed and is more challenging to treat.

The main treatments for metastatic bone disease include medication, radiation therapy, surgical intervention, and tumor ablation therapy. Medication involves pharmaceutical drugs used to manage symptoms, slow disease progression, or address the underlying causes of bone metastases. These treatments are applicable to cancers originating from the breast, lung, thyroid, kidney, prostate, and other sites. The various end-users of these treatments include hospitals, specialty clinics, and ambulatory surgical centers.

The metastatic bone disease market research report is one of a series of new reports that provides metastatic bone disease market statistics, including the metastatic bone disease industry global market size, regional shares, competitors with metastatic bone disease market share, detailed metastatic bone disease market segments, market trends, and opportunities, and any further data you may need to thrive in the metastatic bone disease industry. These metastatic bone disease market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The metastatic bone disease market consists of revenues earned by entities by providing services such as chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The metastatic bone disease market includes sales of intramedullary rods, plates and screws, prosthetic devices, spinal instrumentation, and radiation therapy accessories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.